236 related articles for article (PubMed ID: 33825830)
1. Association analysis of miRNA-related genetic polymorphisms in miR-143/145 and KRAS with colorectal cancer susceptibility and survival.
Wang D; Liu Q; Ren Y; Zhang Y; Wang X; Liu B
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33825830
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis.
Schneiderova M; Naccarati A; Pardini B; Rosa F; Gaetano CD; Jiraskova K; Opattova A; Levy M; Veskrna K; Veskrnova V; Buchler T; Landi S; Vodicka P; Vymetalkova V
Mutagenesis; 2017 Oct; 32(5):533-542. PubMed ID: 29048575
[TBL] [Abstract][Full Text] [Related]
3. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
[TBL] [Abstract][Full Text] [Related]
4. KRAS and VEGF gene 3'-UTR single nucleotide polymorphisms predicted susceptibility in colorectal cancer.
Yang M; Xiao X; Xing X; Li X; Xia T; Long H
PLoS One; 2017; 12(3):e0174140. PubMed ID: 28328959
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of miR-19a inhibits colorectal cancer angiogenesis by suppressing KRAS expression.
Chen M; Lin M; Wang X
Oncol Rep; 2018 Feb; 39(2):619-626. PubMed ID: 29207158
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in microRNA binding sites of mucin genes as predictors of clinical outcome in colorectal cancer patients.
Vymetalkova V; Pardini B; Rosa F; Jiraskova K; Di Gaetano C; Bendova P; Levy M; Veskrnova V; Buchler T; Vodickova L; Naccarati A; Vodicka P
Carcinogenesis; 2017 Jan; 38(1):28-39. PubMed ID: 27803053
[TBL] [Abstract][Full Text] [Related]
7. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.
Pan XM; Sun RF; Li ZH; Guo XM; Zhang Z; Qin HJ; Xu GH; Gao LB
Tumour Biol; 2014 Jan; 35(1):831-5. PubMed ID: 23975373
[TBL] [Abstract][Full Text] [Related]
8. Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome.
Naccarati A; Rosa F; Vymetalkova V; Barone E; Jiraskova K; Di Gaetano C; Novotny J; Levy M; Vodickova L; Gemignani F; Buchler T; Landi S; Vodicka P; Pardini B
Oncotarget; 2016 Apr; 7(17):23156-69. PubMed ID: 26735576
[TBL] [Abstract][Full Text] [Related]
9. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
10.
Liu X; Yang G; Huang J; Chai L; Liu X; Dai Q; Yang Z
Biomark Med; 2020 Jan; 14(1):13-22. PubMed ID: 31729889
[No Abstract] [Full Text] [Related]
11. A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.
Kazmi HR; Chandra A; Kumar S; Satyam LK; Gupta A; Nigam J; Srivastava M; Mittal B
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2577-2583. PubMed ID: 27620744
[TBL] [Abstract][Full Text] [Related]
12. MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42.
Wang YX; Chen YR; Liu SS; Ye YP; Jiao HL; Wang SY; Xiao ZY; Wei WT; Qiu JF; Liang L; Liao WT; Ding YQ
Oncotarget; 2016 Dec; 7(51):84826-84838. PubMed ID: 27769041
[TBL] [Abstract][Full Text] [Related]
13. KRAS polymorphisms are associated with survival of CRC in Chinese population.
Dai Q; Wei HL; Huang J; Zhou TJ; Chai L; Yang ZH
Tumour Biol; 2016 Apr; 37(4):4727-34. PubMed ID: 26515332
[TBL] [Abstract][Full Text] [Related]
14. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH
BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843
[TBL] [Abstract][Full Text] [Related]
15. The polymorphisms of miRNA-binding site in MLH3 and ERCC1 were linked to the risk of colorectal cancer in a case-control study.
Zhang Q; Zheng X; Li X; Sun D; Xue P; Zhang G; Xiao M; Cai Y; Jin C; Yang J; Wu S; Lu X
Cancer Med; 2018 Apr; 7(4):1264-1274. PubMed ID: 29516665
[TBL] [Abstract][Full Text] [Related]
16. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.
Liao WT; Ye YP; Zhang NJ; Li TT; Wang SY; Cui YM; Qi L; Wu P; Jiao HL; Xie YJ; Zhang C; Wang JX; Ding YQ
J Pathol; 2014 Mar; 232(4):415-27. PubMed ID: 24293274
[TBL] [Abstract][Full Text] [Related]
18. A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD.
Hu H; Zhang L; Teng G; Wu Y; Chen Y
Int J Chron Obstruct Pulmon Dis; 2015; 10():1641-9. PubMed ID: 26316738
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
[TBL] [Abstract][Full Text] [Related]
20. Genetic associations between the miRNA polymorphisms miR-130b (rs373001), miR-200b (rs7549819), and miR-495 (rs2281611) and colorectal cancer susceptibility.
Kim EG; Kim JO; Park HS; Ryu CS; Oh J; Jun HH; Kim JW; Kim NK
BMC Cancer; 2019 May; 19(1):480. PubMed ID: 31117970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
